Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 6
Submit an article Journal homepage
35
Views
7
CrossRef citations to date
0
Altmetric
Review

Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository

Simon Dixon University of Sheffield, Sheffield Health Economics Group, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. [email protected]
,
Craig J Currie University of Sheffield, Sheffield Health Economics Group, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. [email protected]
&
Phil McEwan University of Sheffield, Sheffield Health Economics Group, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. [email protected]
Pages 657-665 | Published online: 09 Jan 2014

References

  • Stein CJ, Colditx GA. The epidemic of obesity. J Clin. EndocrinoL Metab. 89, 2522–2525 (2004).
  • Campbell ML, Mathys ML. Pharmacologic options for the treatment of obesity. Am. J Health Syst. Pharm. 58,1301–1308 (2001).
  • Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv. Res. Policy 2, 26–30 (1997).
  • Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, Oxford, UK (1996).
  • Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br. Med. J 323,1300–1303 (2001).
  • Torrance GW. Measurement of health-state utilities for economic appraisal: a review. J Health Econ. 5,1–30 (1986).
  • Dolan P Modeling valuations for EuroQol health states. Med. Care. 35,1095–1108 (1997).
  • Brazier J, Roberts J, Deverill M. The estimation of a preference-based measureof health from the SF-36. J. Health Econ. 21,271-292 (2002).
  • Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health PsychoL 1,61–80 (1982).
  • Feeny D, Furlong W, Torrance GW et aL Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 System. Med. Care 40,113–128 (2002).
  • Hawthorne G. Richardson J. Osborne R. The Assessment of Quality of Life (ApoL) instrument: a psychometric measure of health-related quality of life. QuaL Life Res. 8,209-224 (1999).
  • Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. J Health SErv. Res. Policy 4(3) 174–184 (1999).
  • O'Brien BJ, Spath M, Blackhouse G, Severens JL, Dorian P, Brazier J. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. Health Econ. 12,975–981 (2003).
  • •Clear description of how, and why, different utility instruments can produce wildly different results.
  • Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (ApoL) with four other generic utility instruments. Ann. Med. 33, 358–370 (2001).
  • Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med. Dec:is. Making 20,413–422 (2000).
  • Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 12, 1061–1067 (2003).
  • Oostenbrink RA, Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J. Clin. Epidemiol. 55,791-799 (2002).
  • Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication. QuaL Life Res. 9, 591–601 (2000).
  • Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-ct2b in newly diagnoses multiple myeloma. PharmacoEconomics 12,89–103 (1997).
  • Brazier JE, Kolotkin RL, Crosby RD, Williams GR. Estimating a preference-based single Index for the impact of Weight on Quality Of Life-Lite (IWOOL-Lite) Instrument from the SF-6D. Value Heath 7,490–498 (2004).
  • Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obesity Rey 1, 121–126 (2000).
  • Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health TechnoL Assess. 6(12), 1–153 (2002).
  • Nguyen NT, Goldman C, Rosenquist J et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann. Surg. 234, 279–291 (2001).
  • Kaplan RM Atkins CJ, Wilson DK. The cost-utility of diet and exercise interventions in noninsulin-dependent diabetes mellitus. Health Promotion 2, 331–340 (1998).
  • Salkeld G, Phongsavan P, Oldenburg B et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Pol. 41,105–119 (1997).
  • Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med. Decis Making 24,9–19 (2004).
  • •• Best available cost-effectiveness model of an obesity intervention.
  • Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Am. J. Mea'. 113,491–498 (2002).
  • Trakas K, Oh P, Leiter L, Shear NH. Assessing lifestyle crugs for drug benefit formularies: a cost-utility analysis of orlistat and sibutramine for the treatment of obesity in adults. Value Health 4,53 (2001).
  • Van Gemert WG, Adang EMM, Kop M, Vos G, Greve JWM, Soeters PN. A prospective cost-effectiveness analysis of vertical banded gastroplasty for the treatment of morbid obesity. Obes. Surg. 9, 484–491 (1999).
  • Hakim Z, Wolf A, Garrison LE Estimating the effect of changes in body mass index on health state preferences. PharmacoEconomics 20(6), 393–404 (2002).
  • Groesll EJ, Kaplan RM, Barrett-Connor E, Ganiats TG. Body mass index and quality of life in a community of older adults. Am. J. Prey Med. 26,126–129 (2004).
  • Trakas K, Oh PI, Singh S, Risebrough N, Shear NH. The health status of obese individuals in Canada. Int. j Obes. Re/at. Metab. Disord. 225,662–668 (2001).
  • Livingston EH, Ko CY. Use of the health and activities limitation index as a measure of quality of life in obesity. Obes. Res. 10, 824–832 (2002).
  • Torrence GW. Social preferences for heatlh states: an empirical evaluation of three measurement techniques. Socioecon. Plann. Sc]. 10,129–136 (1976).
  • Erickson P, Wilson R, Shannon I. Years of healthy life (Statistical notes, no. 7). US Department of Health and Human Services, CDC, National Center for Health Statistics, MD, USA (1995).
  • Brazier J, Green C, McCabe C, Stevens K. Use of visual analog scales in economic evaluation. Expert Rev Pharmacoeconomics Outcomes Res. 3, 293–302 (2003) .
  • Hughes D, McGuire A, Elliot H etal. The cost of obesity in the United Kingdom. Drug Assess. 2,327–396 (1999).

Websites

  • British National Formulary www.bnforg.uk (Accessed November 2004)
  • Catalog of preference scores www.hsph.harvard.edu/cearegistry/ (Accessed November 2004)
  • •Good source of utility estimates.
  • Comprehensive table of cost—utility ratios www.hsph.harvard.edu/cearegistry/ (Accessed November 2004)
  • NHS Economic Evaluation Database www.york.ac.uk/inst/crd/nhsdhp.htin (Accessed November 2004)
  • •Good, freely available database of economic evaluations.
  • National Institute for Clinical Excellence www.nice.org.uk a(Accessed November 2004)
  • National Co-ordinating Centre for Health Technology Assessment www.hta.nhsweb.nhs.uk (Accessed November 2004)
  • Health Outcomes Data Respository (HODaR) www.cardiff-research-consortium.co.uk/hodar (Accessed November 2004)
  • ••Large, commercial database of healthoutcomes data.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.